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Background: Insulin resistance is frequent in human immunodeficiency virus (HIV) infection and may be related to
antiretroviral therapy. Cytokines secreted by adipose tissue (adipokines) are linked to insulin sensitivity. The present
study is aimed to assess the prevalence of insulin resistance (IR) and its association with several adipokines, in a
non-diabetic Romanian cohort of men and women with HIV-1 infection, undergoing combination antiretroviral
therapy (cART).
Methods: A cross-sectional study was conducted in an unselected sample of 89 HIV-1-positive, non-diabetic
patients undergoing stable cART for at least 6 months. Metabolic parameters were measured, including fasting
plasma insulin, and circulating adiponectin, leptin, resistin, tumor necrosis factor alpha (TNF-alpha) and interleukin-6
(IL-6) levels. Insulin resistance was estimated by measuring the Quantitative Insulin Sensitivity Check Index (QUICKI),
using a cut-off value of 0.33. A linear regression model was fitted to QUICKI to test the association of IR and
adipokines levels.
Results: A total of 89 patients (aged 18–65, median: 28 years) including 51 men (57.3%) and 38 women (42.7%)
were included in the study. Fifty nine patients (66.3%) were diagnosed with IR based on QUICKI values lower than
the cut-off point. IR prevalence was 72.5% in men and 57.6% in women. The presence of the IR was not influenced
by either the time of the HIV diagnosis or by the duration of cART. Decreased adiponectin and increased serum
triglycerides were associated with increased IR in men (R=0.43, p=0.007). Hyperleptinemia in women was
demonstrated to be associated with the presence of IR (R=0.33, p=0.03).
Conclusions: Given the significant prevalence of the IR in our young non-diabetic cohort with HIV infection
undergoing antiretroviral therapy reported in our study and the consecutive risk of diabetes and cardiovascular
events, we suggest that the IR management should be a central component of HIV-infection therapeutic strategy.
As adipokines play major roles in regulating glucose homeostasis with levels varying according to the sex, we
suggest that further studies investigating adipokines should base their analyses on gender differences.
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The introduction of combination antiretroviral therapy
(cART) has significantly changed the course of human im-
munodeficiency virus (HIV) infection, increasing life ex-
pectancy but also leading to complex clinical and metabolic
changes [1]. The term lipodystrophy was initially used to
summarize these clinical and metabolic modifications [2].
The most important metabolic abnormalities observed in
HIV-patients during cART include: insulin resistance (IR)
with hyperinsulinemia and glucose intolerance [3], hyper-
cholesterolemia with low levels of HDL-cholesterol, hyper-
triglyceridemia, lactic acidemia and hypercoagulopathy [4].
Lipodystrophy also associates fat redistribution: subcuta-
neous lipid stores wasting (Bichat’s fat pad, buttocks and
extremities), central adiposity and fat accumulation in the
dorsocervical region (lipohypertrophy) [2]. As patients with
these metabolic abnormalities have relatively high rates of
experiencing a cardiovascular event, there is growing
concern about the potential damaging impact of cART in
HIV-positive patients. Metabolic abnormalities may result
from various and combined effects of cART antiretroviral
drugs. Several studies have reported that almost all protease
inhibitors (PIs) can cause IR, effects likely caused by the
inhibition of glucose transport mediated by glucose trans-
porter type 4 (GLUT-4) [5,6]. Antiretroviral drugs may also
impair endocrine functions of adipocytes [7]. Adipose tissue
synthesizes various adipokines and hormones, such as
adiponectin, leptin, resistin, tumour necrosis factor-alpha
(TNF-α), interleukins and release free-fatty acids [8].
Adiponectin and leptin may be involved in fat distribution
and insulin sensitivity in HIV-infected patients [9]. Nucleo-
side reverse transcriptase inhibitors (NRTIs) may impair
the secretion of adiponectin and thus may cause IR [10].
The aim of the study was to evaluate the prevalence of
the IR and the association of the IR with clinical and
biological variables, including serum adipokines, in a
Caucasian HIV-infected non-diabetic population of men
and women, undergoing cART.
Methods
A cross-sectional research was performed in a Caucasian
cohort of HIV-1-positive patients attending Prof. Dr.
Matei Bals National Institute of Infectious Diseases from
Bucharest, between June 2009 and June 2010. The
protocol was approved by the Prof. Dr. Matei Bals
National Institute of Infectious Diseases ethics committee
(protocol no. 190/15.01.2009). An informed consent was
obtained from each of the research subjects. The study was
part of a national research grant (SLD-ART no. 62077/
2008) on HIV infected patients. All consecutive non-
diabetic patients who signed a written informed consent to
participate in the study were enrolled. We included
HIV-infected men and women, aged 18 years and over,
undergoing stable cART for at least 6 months. The patientscompleted during the medical visit a standard questionnaire
for demographic parameters and for personal and family
medical histories. Body mass index (BMI) was defined
according to WHO criteria [11]. Overweight was defined as
a BMI ≥ 25 kg/m2 and obesity as BMI ≥ 30 kg/m2.
Blood samples were tested for: Adiponectin (BioSource
ELISA, KAPME09), Resistin (BioSource ELISA, KAPME
50), Leptin (BioSource EASIA KAP2281), Tumor necrosis
factor alpha - TNF-alpha (BioSource EASIA KAP 1751),
Interleukin-6 (IL-6) (BioSource EASIA KAP 1261), CD4 T
cells count (BD FACSCanto II flow cytometer), HIV viral
load (Roche LightCyclerW 480 Real-Time PCR System),
fasting triglycerides, total cholesterol, low-density lipopro-
tein (LDL) cholesterol, high-density lipoprotein (HDL)
cholesterol and fasting plasma glucose (dry slide techno-
logy, Vitros 950, Johnson & Johnson), fasting insulin
(ELx50 Bioelisa Washer BioTek).
IR was determined using the Quantitative Insulin
Sensitivity Check Index (QUICKI), calculated as 1/(log
(fasting insulin μU/mL) + log(fasting glucose mg/dL) [12].
In normal populations, mean QUICKI levels range
from 0.37 to 0.39 [13]. Consistent with previous studies,
QUICKI values were dichotomized at the cut-off of 0.33,
lower levels signifying IR [13-15].
We also assessed the homeostatic model assessment –
insulin resistance (HOMA-IR) index, first described by
Matthews et al. in 1985 [16]. The formula used to calculate
HOMA-IR was:
HOMA-IR = fasting insulin (μU/mL) × fasting plasma
glucose (mmol/L)/22.
We assumed a HOMA-IR value of > 3 to define IR,
consistent with previous studies investigating insulin
resistance in Caucasian HIV populations [17].
Statistical analyses
In order to test whether the samples came from normally
distributed populations we used the Shapiro–Wilk test.
Variables with gaussian distribution were expressed as
means (+/−standard deviation [SD]). For non-normally
distributed continuous data results were presented as me-
dian (interquartile range). Differences in means between
groups were tested using independent-sample t-tests. We
calculated the 95% confidence interval for the difference
between the population means. Mann–Whitney test for
non parametric continuous variables, Chi-square or
Fisher’s exact test for categorical variables were used to
test for statistical significance. Linear regression models
were fitted to QUICKI score to test the association of IR
with normally distributed continuous variables, included
in the multivariate models either because of their known
or suspected association with IR or based on an observed
univariate association with QUICKI. Serum triglycerides,
Arama et al. BMC Endocrine Disorders 2013, 13:4 Page 3 of 7
http://www.biomedcentral.com/1472-6823/13/4adiponectin, leptin, resistin, IL-6, TNF-alpha values were
natural log transformed for the linear regression analysis.
The correlation coefficient (R) was calculated to assess the
linear correlation between the observed and model-
predicted values of the dependent variables. We computed
two-tailed p-values. Statistical significance was set at 5%,
and all analyses were performed with SPSSW Statistics
v.17.0, IBMW, New York, USA.
Results and discussion
A total of 89 patients (age 18–65, median: 28 years) inclu-
ding 51 men (57.3%, age range: 18–63 years, median:
32 years) and 38 women (42.7% age range: 19–65 years,
median: 21 years) were included in the study. The mean
BMI was 23.6 (± 3.9) kg/m2. The median time from HIV
diagnosis was 80.5 months and the median time on
antiretroviral therapy was 72.5 months. Sixty five
patients (73%) had a current PI-based cART regimen.
Median serum levels of adiponectin, leptin, resistin,Table 1 Clinical and biological characteristics of study patien
Characteristics Total patients Pati
N 89
Age (years) a 28 (22)
Males 51 (57.3)
BMI (kg/m2) 23.6 ± 3.9
Fasting glucose (mg/dl) 85.7 ± 13.7
Haemoglobin A1c (%) 4.85 ± 0.39
Hypertension b 23 (25.8)
CD4 Tcell (cells/mm3) a 440 (402)
Patients with undetectable HIV viral load 65 (73)
Time on antiretroviral therapy (months) a 72.5 (95)
Time from HIV diagnosis (months) a 80.5 (83)
Current Protease Inhibitor treatment 65 (73)
Total cholesterol (mg/dl) 192 ± 38.4
HDL cholesterol (mg/dl) 43.9 ± 12.4
LDL cholesterol (mg/dl) 111.87 ± 35.4
Triglycerides (mg/dl) a 166 (129)
Dyslipidemia c 71 (79.8)
Hypertriglyceridemia d 54 (60.7)
Adiponectin (μg/mL) a 10.2 (12.5)
Leptin (ng/mL) a 1.4 (3.6)
Resistin (ng/mL)a 5.5 (3.6)
TNF alfa (pg/mL)a 10.3 (15.1)
IL-6 (pg/mL) a 26.5 (10.3)
Data are shown as mean ± SD or number (percent).
a Results presented as median (interquartile range).
b Hypertension defined as blood pressure ≥130/≥85 mm Hg or antihypertensive me
c Dyslipidemia defined as elevation of one of the following: total cholesterol, LDL ch
d Hypertriglyceridemia defined as serum triglycerides ≥150 mg/dl.
* p<0.05 Group 1 vs. Group 2.
p values based on t-test for equality of means or Mann–Whitney test for continuouTNF alpha and IL-6 were 10.2 μg/mL, 1.4 ng/mL,
5.5 ng/mL, 10.3 pg/mL and 26.5 pg/mL, respectively.
Fifty nine patients (66.3%) were diagnosed with IR based
on QUICKI values lower than the cut-off point. The overall
prevalence of IR was 62.9%, based on HOMA-IR dichoto-
mization. The median value of HOMA-IR was 3.77 (3.62).
The patients were divided into Group 1 (patients
without IR) and Group 2 (patients with IR). Group 1
patients had a mean QUICKI value of 0.35 (±0.02)
and a median HOMA-IR of 1.84 (0.67) vs. 0.29
(±0.02) and 4.62 (3.48) in Group 2, respectively. The
subject characteristics stratified by IR status are
shown in Table 1. Significant differences were noted
in total cholesterol, triglycerides and adiponectin serum
levels between the two groups. The prevalence of IR was
not significantly different between men and women. No
significant differences were found between Group 1 and
Group 2 in age, BMI, total time on cART or current
protease inhibitor treatment.ts by IR
ents without IR (Group 1) Patients with IR (Group 2) P
30 (33.7) 59 (66.3)
20.5 (13) 33 (25) 0.12
14 (46.7) 37 (62.7) 0.14
22.6 ± 3.8 24.2 ± 3.8 0.3
82.3 ± 8.6 87.2 ± 15 0.12
4.82 ± 0.25 4.86 ± 0.43 0.66
8 (26.7) 15 (25.4) 1.00
525 (470) 428 (370) 0.38
20 (66.7) 45 (76.3) 0.33
80 (120) 70.5 (95) 0.21
92 (96) 76 (64) 0.36
23 (76.7) 42 (71.2) 0.58
181.9 ± 33 199.6 ± 39.9 0.04*
42.9 ± 10.5 44.3 ± 13.3 0.53
107.3 ± 32.7 114.1± 36.8 0.39
151.5 (79) 181 (169) 0.04*
24 (80) 47 (79.7) 1.00
16 (53.3) 38 (64.4) 0.36
16 (28.8) 9.4 (10.7) 0.00*
1.8 (2.9) 1.3 (4.1) 0.53
5.2 (5.1) 5.7 (3.4) 0.63
11.9 (16.2) 9.7 (15) 0.62
26.6 (23.1) 26.5 (8.4) 0.52
dication.
olesterol, triglyceride serum concentrations or a decrease of HDL cholesterol.
s variables, Chi-square or Fisher’s exact test for categorical variables.
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tory parameters and IR, first we assessed the relationship
of all individual variables with QUICKI score by fitting a
linear regression model. The variables with univariate
association to QUICKI were further tested to improve
the model predictivity. After all variables were tested in
the univariate analysis for the entire population, including
BMI and age, only log transformed triglycerides serum
levels (LOGTriglycerides) were significantly associated
with QUICKI (R=0.24, p=0.01).
Fifity one men were enrolled in the study and 37 (72.5%)
were diagnosed with IR. Male subject characteristics strati-
fied by IR status are shown in Table 2. Significant between-
group differences persisted in triglycerides and adiponectin
serum levels. The significant variables selected to build the
additive linear regression model in men, the estimate terms
for the model and corresponding test statistics are provided
in Table 3. Of the variables tested only log transformed
adiponectin (LOGAdiponectin) and LOGTriglycerides
had a significant effect on QUICKI values in our
cohort of male subjects. Taken together, the analysis
indicates that LOGAdiponectin with LOGTriglycerides
were associated with QUICKI index (R=0.43, p=0.007) in
males. The additive models that included age and BMI
together with LOGAdiponectin and LOGTriglycerides
lacked statistical significance.
Of 38 women enrolled 22 (57.6%) were diagnosed with
IR. Female laboratory characteristics stratified by IR status
are shown in Table 2. Significant between-group diffe-
rences were observed in HDL cholesterol and leptin serum
levels. In women, of all variables tested in the univari-
ate analysis, only log transformed leptin serum levels
(LOGLeptin) were significantly associated with QUICKI






N 14 (27.5) 37 (72.5)
Adiponectin (μg/mL) a 14.1 (31.8) 8.3 (10.5)
Leptin (ng/mL) a 0.6 (1.2) 0.9 (1.2)
Resistin (ng/mL)a 4.9 (3.3) 5.5 (3)
TNF alpha (pg/mL)a 13.8 (17.6) 10.4 (14.6)
IL-6 (pg/mL) a 35.8 (22.6) 27.7 (18.5)
Total cholesterol (mg/dl) 179.5± 33 197.6± 35.8
LDL cholesterol (mg/dl) 107.7± 34 115± 37.2
HDL cholesterol (mg/dl) 42.2± 12.5 40 ± 9.1
Triglycerides (mg/dl) a 117.5 (84) 217 (157)
Data are shown as mean ± SD or number (percent).
a Results presented as median (interquartile range).
* p<0.05 Group 1 vs. Group 2.
p values based on t-test for equality of means or Mann–Whitney test for continuouincluding age and BMI, did not show any improvement of
our additive model.
IR appears when maintaining normal physiological
values of glycaemia require insulin levels that exceed
normal concentrations [18]. IR is associated with the
development of diabetes and obesity [19]. Up to 20% of
non-HIV western population may have IR [20,21].
Several studies reported a two-fold increase of cardiovas-
cular risk compared to non-insulin resistant controls
[22,23]. In the pre-cART era several cross-sectional
studies reported slightly increased [24] or normal [25]
insulin sensitivity when compared to uninfected con-
trols. cART introduction led to increases in fasting insu-
lin and decreases in insulin sensitivity, effects dependent
both on the class of the antiretroviral used and the dif-
ferent antiretrovirals within each class [26,27]. Different
studies have evaluated the prevalence of IR at 20 to 50%,
in HIV-positive patients [28]. We noted higher levels of
IR than reported by previous studies, independent of
current treatment with PIs and of BMI, which may be
attributed in part to our method of assessment. QUICKI
has a very good correlation with the glucose clamp index
of insulin sensitivity, which is considered the gold stan-
dard method for IR assessment [15]. IR presence in our
population of HIV-positive young adults was not influ-
enced either by the time from HIV diagnosis or to the
duration of cART. This finding may suggest that the
effect of cART on IR may not have a cumulative or
long-term response, a similar result being reported also
by other studies [29]. As IR presence is associated with
an increased risk of diabetes, cardiovascular events,
stroke and death, the reduction of its prevalence must be
considered an essential therapeutic target in HIV-patients
undergoing retroviral therapy.atients by IR
Females





16 (42.1) 22 (57.6)
0.03* 18.1 (28.1) 14.4 (12.7) 0.18
0.25 2.8 (2.3) 5.3 (8.8) 0.04*
0.8 5.3 (6) 6.2 (4.6) 0.5
0.65 10.4 (14.3) 8.9 (14.8) 0.62
0.46 23.9 (14.4) 25.2 (4.9) 0.22
0.1 184± 34 202.9± 46.6 0.17
0.52 107± 32.6 112± 36.9 0.62
0.19 41.7± 8.5 48 ± 16 0.02*
0.01* 167.5 (41) 165.5 (140) 0.96
s variables, Chi-square or Fisher’s exact test for categorical variables.
Table 3 Multivariate analysis: effect of selected variables (LOGAdiponectin, LOGTriglycerides) on QUICKI (dependent
variable) in male subjects
Independent Variables Unstandardized Coefficients (B) Standardized Coefficients (beta) 95% Confidence interval for B P
LOGAdiponectin b 0.009 0.278 (0.000; 0.001) 0.04
LOGTriglycerides b −0.013 −0.261 (−0.026; 0.01) 0.03
bLOGAdiponectin - log transformed adiponectin serum levels computed variable for linear regression.
bLOGTriglycerides - log transformed triglycerides serum levels computed variable for linear regression.
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and has an important role as a mediator of peroxisome
proliferator-activated receptor gamma action [30]. Adipo-
nectin may increase insulin responsiveness of the glucose
transport system in adipocytes through increased GLUT4
gene expression and increased GLUT4 recruitment to the
plasma membrane [31]. Several studies have reported that
adipocyte differentiation was perturbed both in vitro and
in vivo as a direct effect of cART and the consecutive
decrease in serum adiponectin levels was associated with
insulin resistance [32,33]. We found an inverse correlation
between adiponectin and IR in men, but not in females
which partially concurs with previous studies. Vigouroux
et al. (2003) have also reported that adiponectin was posi-
tively correlated with insulin sensitivity in a cohort of 131
HIV-infected men with PI-based cART regimens [9]. In a
study on 237 Afro-Caribbean HIV-1-infected patients, pub-
lished in 2011, Deloumeaux et al. found also an inverse
correlation between adiponectin and IR in both men and
women. After adjusting for clinical and metabolic para-
meters, the correlation between adiponectin and insulin
resistance was observed only in women [34], a conclusion
that contradicts our results and the previously mentioned
study. Alterations of serum adiponectin concentration in
relation to insulin resistance was also observed in a cohort
of HIV-infected youths (aged 5.0 - 19.4 years), in a study
published by Viganò et al. in 2011, which did not take into
account sex differences but evaluated lipodystrophy. Low
adiponectin concentration was associated to central
fat and mixed lipohypertrophy and to signs of IR [35].
Other studies have also shown that adiponectin was
inversely associated with IR, type 2 diabetes and obesity in
HIV and non HIV-patients in without adjusting for gender
differences [36,37].
Leptin is a 167-amino-acid adipokine secreted mainly
by white adipose tissue. The levels of leptin are positively
correlated with the amount of body fat [37]. Leptin regu-
lates energy homeostasis and various neuroendocrine
functions [38]. Our data showed higher levels of leptinTable 4 Univariate analysis: effect of selected variables (LOGL
Independent Variables Unstandardized Coefficients (B) Standar
LOGLeptin c −0.012
cLOGLeptin - log transformed leptin serum levels computed variable for linear regrein women with IR vs women without IR and a weak cor-
relation between IR presence and leptin, observed in the
linear regression model, with QUICKI as dependent and
LOGLeptin as independent variable. Leptin did not con-
tribute to an improvement of our linear model of IR in
men. Other studies investigating this association have
reported inconclusive results but very few have based
their analyses on gender differences. Azzoni et al. in
2010 observed that serum leptin levels are inversely
associated with HIV replication, independent of disease
progression. In the same study, the authors reported a weak
association between leptin levels and the Homeostatic
Model Assessment for Insulin Resistance (HOMA-IR) [39].
Mynarcik et al. (2002) found that levels of leptin did not
correlate with insulin sensitivity, in HIV-infected subjects
with body fat redistribution [37]. In other study investiga-
ting adipokines and antiretroviral therapy related lipody-
strophy, Tao et al. (2009) observed that leptin was positively
correlated with the levels of total body fat, limb fat, and
trunk fat, both in lipodystrophic and patients without body
fat redistribution, but did not correlate with IR, and might
serve only as a biomarker for total body fat mass [40].
Nagy et al. (2003) found a significant association between
leptin concentrations and IR in patients with different
morphological phenotypes. The lowest mean leptin levels
were observed in patients with lipoatrophic changes.
Hypoleptinemia was independently associated with IR in
patients with lipoatrophy. Highest leptin concentrations
were observed in patients with lipohypertrophy. Leptin
levels in between the two extremes were observed in sub-
jects with no body shape changes [41]. The role of leptin
alterations in IR pathogenesis remains to be clarified by
future long-term and prospective studies.
Despite the relative low number of patients, our study
has several strengths. This is the first study in Romania to
investigate adipokine dysregulation in association with
HIV metabolic abnormalities during cART. The young age
of our cohort is a distinct feature for the HIV epidemiology
in Romania, compared with western European countries.eptin) on QUICKI (dependent variable) in female subjects
dized Coefficients (beta) 95% Confidence interval for B P
−0.339 (−0.023; 0.000) 0.03
ssion.
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childhood and adolescence between 1980–1990. QUICKI
was used in order to diagnose IR, which is one of the most
accurate surrogate indexes for determining insulin sensiti-
vity in humans. Very few studies have evaluated untill now
IR risk factors based on sex differences. Factors associated
with IR, which have been lacking in previous studies,
including the time from HIV diagnosis and the time on
cART were measured and evaluated in our analyses.
Our study has some limitations. Correlations were small
to moderate in magnitude. The association between IR and
adiponectin/triglycerides in men and IR and leptin in
women disappeared after including age and BMI in the
regression models. This may be caused by BMI variations
and changes in adiponectin with age that may contribute to
IR pathogenesis and also by the low number of enrolled
patients, with loss of statistical power as more variables
were added. QUICKI was used to diagnose IR, a surrogate
method, which has some limitations, such as the absence of
a definite threshold for IR in Caucasian populations.
QUICKI requires the quantification of fasting plasma insu-
lin. Similar observations in clinical practice may be
predicted with the use of International Diabetes Federation
(IDF) or Adult Treatment Panel III (ATPIII) definitions of
metabolic syndrome, which may provide cheaper ways for
detecting patients at risk of diabetes and cardiovascular
events. As leptin may be positively correlated with the levels
of total body fat, limb fat, and trunk fat [41], the predictive
value of our model might have been improved if we had
included body fat redistribution in our analysis.
Conclusions
We report a significant prevalence of IR in a young non-
diabetic Caucasian population with HIV infection under-
going antiretroviral therapy that was independent of the
time of the HIV diagnosis. Hypoadiponectinemia in men
and hyperleptinemia in women was demonstrated to be
associated with IR presence which brings new data to
support the role of these cytokines in IR pathogenesis. As
adipokines play major roles in regulating glucose homeosta-
sis with levels varying according to sex, we suggest that fur-
ther studies investigating adipokines should base their
analyses on gender differences. In addition, new studies are
needed to investigate the mechanisms contributing to the
significant differences observed between men and women.
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